Tags: Drug.
Cixutumumab is a monoclonal antibody for the treatment of solid tumors.This drug was developed by ImClone Systems Inc. under the name IMC-A12.It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway.